WHAT IS CLAIMED:

1. An oligomeric compound, according to the following chemical structure:



(SEQ ID NO: 1448), or a pharmaceutically acceptable salt thereof.

2. An oligomeric compound, according to the following chemical structure:



(SEQ ID NO: 1448).

3. An oligomeric compound comprising a modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence SEQ ID NO: 1448, wherein the modified oligonucleotide comprises

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of three linked nucleosides; and a 3' wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein the 5' wing segment and the 3' wing segment comprise cEt sugars; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

4. The oligomeric compound of claim 1, which is a sodium salt or a potassium salt.

5. A pharmaceutical composition comprising the oligomeric compound of any one of claims 1-4 and a pharmaceutically acceptable diluent.

6. The pharmaceutical composition of claim 5, wherein the pharmaceutically acceptable diluent is water.

7. Use of an oligomeric compound of any one of claims 1-4 in the manufacture of a medicament for treating a disease associated with HSD17B13 in an individual, wherein the compound is to be administered to the individual.

8. The use of claim 7, wherein the individual has a liver disease, NAFLD, NASH, alcoholic steatohepatitis (ASH), alcoholic liver disease, nonalcoholic liver disease, alcoholic cirrhosis, nonalcoholic cirrhosis, steatohepatisis, hepatic steatosis, hepatocellular carcinoma, alcoholic liver disease, HCV hepatitis, chronic hepatitis, hereditary hemochromatosis, or primary sclerosing cholangitis.

9. Use of an oligomeric compound of any one of claims 1-4 in the manufacture of a medicament for inhibiting expression of HSD17B13 in a cell, wherein the cell is to be contacted with the oligomeric compound.

10. The use of claim 9, wherein the cell is in the liver of an individual.

11. The use of claim 10, wherein the individual has, or is at risk of having, liver disease, NAFLD, NASH, alcoholic steatohepatitis (ASH), alcoholic liver disease, nonalcoholic liver disease, alcoholic cirrhosis, nonalcoholic cirrhosis, steatohepatisis, hepatic steatosis, hepatocellular carcinoma, alcoholic liver disease, HCV hepatitis, chronic hepatitis, hereditary hemochromatosis, or primary sclerosing cholangitis.

12. Use of an oligomeric compound of any one of claims 1-4 in the manufacture of a medicament for ameliorating liver damage, steatosis, liver fibrosis, liver inflammation, liver scarring or cirrhosis, liver failure, liver enlargement, elevated transaminases, or hepatic fat accumulation in an individual, wherein the oligomeric compound is to be administered to the individual.

13. The use of claim 12, wherein the individual has, or is at risk of having, liver disease,

NAFLD, NASH, alcoholic steatohepatitis (ASH), alcoholic liver disease, nonalcoholic liver disease, alcoholic cirrhosis, nonalcoholic cirrhosis, steatohepatisis, hepatic steatosis, hepatocellular carcinoma, alcoholic liver disease, HCV hepatitis, chronic hepatitis, hereditary hemochromatosis, or primary sclerosing cholangitis.